Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research
Por:
Sanchez-Guijo, F, Garcia-Olmo, D, Prosper, F, Martinez, S, Zapata, A, Fernandez-Aviles, F, Toledo-Aral, JJ, Torres, M, Farinas, I, Badimon, L, Labandeira-Garcia, JL, Garcia-Sancho, J, Moraleda, JM
Publicada:
1 ene 2020
Resumen:
In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practicecertified cell manufacturing facilities and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients. Crown Copyright (C) 2019. Published by Elsevier Inc. on behalf of International Society for Cell and Gene Therapy. All rights reserved.
Filiaciones:
Sanchez-Guijo, F:
Univ Salamanca, Serv Hematol, IBSAL Hosp Univ Salamanca, CIC, Salamanca, Spain
Univ Salamanca, CIBERONC, Salamanca, Spain
Garcia-Olmo, D:
Univ Autonoma Madrid, Fdn Jimenez Diaz, Univ Hosp, Madrid, Spain
Prosper, F:
Univ Navarra, Serv Hematol & Terapia Celular, Clin Univ Navarra, Pamplona, Spain
Univ Navarra, CIMA, Pamplona, Spain
Martinez, S:
CIBERSAM, CSIC, UMH, Inst Neurociencias, Alicante, Spain
Zapata, A:
Univ Complutense Madrid, Dept Cell Biol, Madrid, Spain
Fernandez-Aviles, F:
Univ Complutense Madrid, CIBERCV, Serv Cardiol, IiSGM Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Toledo-Aral, JJ:
Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilia IBiS, Seville, Spain
Torres, M:
CNIC, Cardiovasc Dev Program, Madrid, Spain
Farinas, I:
Univ Valencia, Dept Biol Celular Biol Func & Antropol Fis, Estruct Recerca Interdisciplinar Biotecnol & Biom, Valencia, Spain
Univ Valencia, CIBERNED, Valencia, Spain
Badimon, L:
Autonoma Univ Barcelona, ICCC Program, IR Hosp Santa Creu I St Pau, Barcelona, Spain
Labandeira-Garcia, JL:
Univ Santiago de Compostela, Res Ctr Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain
Networking Res Ctr Neurodegenerat Dis CIBERNED, Santiago De Compostela, Spain
Garcia-Sancho, J:
Univ Valladolid, IBGM, Valladolid, Spain
Moraleda, JM:
Univ Murcia, IMIB, Serv Hematol, Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain
Hybrid Gold
|